It is noteworthy that none of the three patients who had tumor tissue collected for molecular analysis at recurrence showed ESR1 mutations which have been associated with resistance to aromatase inhibitors in ER+ metastatic breast cancer [57]. The gene discussed is ESR1; the disease is neoplasm.